ATRA News and Press, Atara Biotherapeutics Inc.

ATRA - Atara lead asset tab-cel undergoes FDA priority review

2024-07-17 15:39:52 ET More on Atara Biotherapeutics Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy Atara Biotherapeutics announces reverse split to regain Nasdaq compliance Seeking Alpha’s Quant Rating on Atara Bi...

ATRA - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...

ATRA - Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...

ATRA - Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

2024-07-03 13:39:37 ET Summary Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications, with a world-first allogeneic CAR-T approval in Europe and nearing FDA approval. Assuming no regulatory delays ATRA is well-funded t...

ATRA - How to Take Advantage of moves in (ATRA)

2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

ATRA - Atara Biotherapeutics' Ebvallo(TM) (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases

Ebvallo is the First and Only Approved Therapy in Europe for Adults and Children with EBV+ PTLD Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies ...

ATRA - ATRA announced stock split 1-25

2024-06-20 09:02:05 ET Atara Biotherapeutics Inc (ATRA) announced stock split at a ratio of 1-for-25 on 2024-06-20 ... Full story available on KlickAnalytics.com

ATRA - Atara Biotherapeutics announces reverse split to regain Nasdaq compliance

2024-06-17 08:24:32 ET More on Atara Biotherapeutics Seeking Alpha’s Quant Rating on Atara Biotherapeutics Historical earnings data for Atara Biotherapeutics Financial information for Atara Biotherapeutics Read the full article on Seeking Alpha ...

ATRA - Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it will conduct a reverse stock split...

ATRA - Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...

Company Name:	Atara Biotherapeutics Inc.
Stock Symbol:	ATRA
Market:	NASDAQ
Website:	atarabio.com